<VariationArchive VariationID="466546" VariationName="NM_025137.4(SPG11):c.5925_5934dup (p.Val1979Ter)" VariationType="Duplication" Accession="VCV000466546" Version="5" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-05-08" DateCreated="2017-12-26" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="465073" VariationID="466546">
      <GeneList>
        <Gene Symbol="SPG11" FullName="SPG11 vesicle trafficking associated, spatacsin" GeneID="80208" HGNC_ID="HGNC:11226" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q21.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="44562696" stop="44663662" display_start="44562696" display_stop="44663662" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="44854893" stop="44955875" display_start="44854893" display_stop="44955875" Strand="-" />
          </Location>
          <OMIM>610844</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_025137.4(SPG11):c.5925_5934dup (p.Val1979Ter)</Name>
      <CanonicalSPDI>NC_000015.10:44574973:TTCCAGGTTA:TTCCAGGTTATTCCAGGTTA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>15q21.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="44574973" stop="44574974" display_start="44574973" display_stop="44574974" variantLength="10" positionVCF="44574973" referenceAlleleVCF="C" alternateAlleleVCF="CTTCCAGGTTA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="44867171" stop="44867172" display_start="44867171" display_stop="44867172" variantLength="10" positionVCF="44867171" referenceAlleleVCF="C" alternateAlleleVCF="CTTCCAGGTTA" />
      </Location>
      <ProteinChange>V1979*</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.44574974_44574983dup" Assembly="GRCh38">
            <Expression>NC_000015.10:g.44574974_44574983dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.44867172_44867181dup" Assembly="GRCh37">
            <Expression>NC_000015.9:g.44867172_44867181dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008885.1" sequenceAccession="NG_008885" sequenceVersion="1" change="g.93696_93705dup">
            <Expression>NG_008885.1:g.93696_93705dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_025137.4" sequenceAccession="NM_025137" sequenceVersion="4" change="c.5925_5934dup" MANESelect="true">
            <Expression>NM_025137.4:c.5925_5934dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_079413.3" sequenceAccession="NP_079413" sequenceVersion="3" change="p.Val1979Ter">
            <Expression>NP_079413.3:p.Val1979Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001160227.2" sequenceAccession="NM_001160227" sequenceVersion="2" change="c.5867-2163_5867-2154dup">
            <Expression>NM_001160227.2:c.5867-2163_5867-2154dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_025137.3" sequenceAccession="NM_025137" sequenceVersion="3" change="c.5925_5934dupTAACCTGGAA">
            <Expression>NM_025137.3:c.5925_5934dupTAACCTGGAA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA7534305" DB="ClinGen" />
        <XRef Type="rs" ID="749652788" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00001" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_025137.4(SPG11):c.5925_5934dup (p.Val1979Ter) AND Hereditary spastic paraplegia 11" Accession="RCV000542835" Version="6">
        <ClassifiedConditionList TraitSetID="295">
          <ClassifiedCondition DB="MedGen" ID="C1858479">Hereditary spastic paraplegia 11</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-11" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-11" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2017-12-26" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19105190</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20110243</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22154821</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26556829</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33638609</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="295" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3739" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, COMPLICATED, WITH THIN CORPUS CALLOSUM</ElementValue>
                <XRef Type="MIM" ID="604360" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SPASTIC PARAPLEGIA, AUTOSOMAL RECESSIVE, WITH MENTAL IMPAIRMENT AND THIN CORPUS CALLOSUM</ElementValue>
                <XRef Type="MIM" ID="604360" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Nakamura Osame syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Autosomal recessive hereditary spastic paraplegia, mental impairment, and thin corpus callosum</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spastic paraplegia 11, autosomal recessive</ElementValue>
                <XRef ID="Spastic+paraplegia+11/6677" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spastic paraplegia 11</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary spastic paraplegia mental impairment and thin corpus callosum</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary spastic paraplegia 11</ElementValue>
                <XRef ID="MONDO:0011445" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Spastic paraplegia,  mental retardation and thin corpus callosum</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HSP-TCC</ElementValue>
                <XRef Type="MIM" ID="604360" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">SPG11</ElementValue>
                <XRef Type="MIM" ID="604360" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Spastic paraplegia 11 (SPG11) is characterized by progressive spasticity and weakness of the lower limbs frequently associated with the following: mild intellectual disability with learning difficulties in childhood and/or progressive cognitive decline; peripheral neuropathy; pseudobulbar involvement; and increased reflexes in the upper limbs. Less frequent findings include: cerebellar signs (ataxia, nystagmus, saccadic pursuit); retinal degeneration; pes cavus; scoliosis; and parkinsonism with characteristic brain MRI features that include thinning of the corpus callosum. Onset occurs mainly during infancy or adolescence (range: age 1-31 years) and in rare cases as late as age 60 years. Most affected individuals become wheelchair bound one or two decades after disease onset.</Attribute>
                <XRef ID="NBK1210" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="4919" />
                <XRef ID="4919" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301389</ID>
                <ID Source="BookShelf">NBK1210</ID>
              </Citation>
              <XRef ID="2822" DB="Orphanet" />
              <XRef ID="C1858479" DB="MedGen" />
              <XRef ID="MONDO:0011445" DB="MONDO" />
              <XRef Type="MIM" ID="604360" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5503592" SubmissionDate="2023-01-07" DateLastUpdated="2023-01-15" DateCreated="2023-01-15">
        <ClinVarSubmissionID localKey="NM_025137.3:c.5934_5935insTAACCTGGAA|OMIM:604360" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002818536" DateUpdated="2023-01-15" DateCreated="2023-01-15" Type="SCV" Version="1" SubmitterName="Department of Neurology, The Affiliated Hospital of Zunyi Medical University" OrgID="508902" OrganizationCategory="other" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-04">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This nucleotide variation could lead to the change of the codon compiling the Val1979 amino acid into a stop codon (p.Val1979Ter), resulting in the premature termination of peptide chain synthesis, which was a nonsense variation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <GeographicOrigin>Guizhou Province, China</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">20</Age>
              <Age Type="maximum" age_unit="years">29</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory" dateValue="2018-05-07">Beijing Kangxu Institute of Medical Laboratory</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_025137.3:c.5934_5935insTAACCTGGAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604360" Type="MIM" />
          </Trait>
        </TraitSet>
        <Comment>In silico analysis of the mutant sequences was performed. The pathogenic significance of mutations (c.6738_6739insT, c.5934_5935insTAACCTGGAA) was analyzed based on reference sequence NM_025137.3 and NP_079413.3 (SPG11 gene) by different software tools including MutationTaster (http://www. mutationtaster.org/), PolyPhen-2 (Polymorphism Phenotyping) (http://genetics.bwh.harvard.edu/pph2/), PROVEAN (Protein Variation Effect Analyzer) (http://provean. jcvi.org/index.php), and CADD (Combined Annotation ependent Depletion). The results of in silico analysis showed that the mutations predicated to be disease-causing variants by MutationTaster, probably damaging by PolyPhen-2, deleterious by PROVEAN, and deleterious and pathogenic by CADD (PHRED score 25 for both variants).</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB12518422</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1234795" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="771057|MedGen:C1858479" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000642258" DateUpdated="2024-02-20" DateCreated="2017-12-26" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19105190</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20110243</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22154821</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26556829</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33638609</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Val1979*) in the SPG11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG11 are known to be pathogenic (PMID: 19105190, 20110243, 22154821, 26556829). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with hereditary spastic paraplegia (PMID: 33638609). ClinVar contains an entry for this variant (Variation ID: 466546). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPG11" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000015.9:g.44867171_44867172insTTCCAGGTTA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1858479" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB3109251</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1234795" TraitType="Disease" MappingType="XRef" MappingValue="C1858479" MappingRef="MedGen">
        <MedGen CUI="C1858479" Name="Hereditary spastic paraplegia 11" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5503592" TraitType="Disease" MappingType="XRef" MappingValue="604360" MappingRef="OMIM">
        <MedGen CUI="C1858479" Name="Hereditary spastic paraplegia 11" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

